Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

ClinicalTrials.gov ID: NCT00699166

Public ClinicalTrials.gov record NCT00699166. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter 2-Week Pilot Study to Evaluate the Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) Given Orally in Female Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the tolerability, safety and efficacy of DNK333 against diarrhea caused by Irritable Bowel Syndrome in women.

Study identification

NCT ID: NCT00699166
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Novartis; Industry
Enrollment: 135 participants

Conditions and interventions

Conditions

Irritable Bowel Syndrome

Interventions

DNK333 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2004
Primary completion: Aug 31, 2005
Completion: Aug 31, 2005
Last update posted: Jun 16, 2008

2004 – 2005

United States locations

U.S. sites: 29
U.S. states: 18
U.S. cities: 29

Facility	City	State	ZIP	Site status
Not listed	Anniston	Alabama	36207	—
Not listed	Huntsville	Alabama	35801	—
Not listed	Northport	Alabama	35476	—
Not listed	Tucson	Arizona	85712	—
Not listed	North Little Rock	Arkansas	72117	—
Not listed	Orange	California	92869	—
Not listed	Riverside	California	92506	—
Not listed	San Diego	California	92108	—
Not listed	Torrance	California	90505	—
Not listed	Bristol	Connecticut	06010	—
Not listed	Hartford	Connecticut	06106	—
Not listed	Hollywood	Florida	33021	—
Not listed	Indianapolis	Indiana	46260	—
Not listed	Arkansas City	Kansas	67005	—
Not listed	Lexington	Kentucky	40504	—
Not listed	Boston	Massachusetts	02215	—
Not listed	Mexico	Missouri	65265	—
Not listed	Washington	Missouri	63090	—
Not listed	Lincoln	Nebraska	68503	—
Not listed	Dayton	Ohio	45440	—
Not listed	Oklahoma City	Oklahoma	73104	—
Not listed	Tulsa	Oklahoma	74135	—
Not listed	Beaver Falls	Pennsylvania	15010	—
Not listed	Chattanooga	Tennessee	37404	—
Not listed	Memphis	Tennessee	38119	—
Not listed	Nashville	Tennessee	37205	—
Not listed	Austin	Texas	78758	—
Not listed	Lake Jackson	Texas	77566	—
Not listed	Salt Lake City	Utah	84102	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00699166, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 16, 2008 · Synced Sep 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00699166 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →